Anker, Markus S. (35763654100)Markus S. (35763654100)AnkerHadzibegovic, Sara (57204551985)Sara (57204551985)HadzibegovicLena, Alessia (57204551352)Alessia (57204551352)LenaBelenkov, Yury (7006528098)Yury (7006528098)BelenkovBergler-Klein, Jutta (56019537300)Jutta (56019537300)Bergler-Kleinde Boer, Rudolf A. (8572907800)Rudolf A. (8572907800)de BoerFarmakis, Dimitrios (55296706200)Dimitrios (55296706200)Farmakisvon Haehling, Stephan (6602981479)Stephan (6602981479)von HaehlingIakobishvili, Zaza (6603020069)Zaza (6603020069)IakobishviliMaack, Christoph (6701763468)Christoph (6701763468)MaackPudil, Radek (57210201747)Radek (57210201747)PudilSkouri, Hadi (21934953600)Hadi (21934953600)SkouriCohen-Solal, Alain (57189610711)Alain (57189610711)Cohen-SolalTocchetti, Carlo G. (6507913481)Carlo G. (6507913481)TocchettiCoats, Andrew J.S. (35395386900)Andrew J.S. (35395386900)CoatsSeferović, Petar M. (6603594879)Petar M. (6603594879)SeferovićLyon, Alexander R. (57203046227)Alexander R. (57203046227)Lyon2025-06-122025-06-122019https://doi.org/10.1002/ehf2.12551https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078504644&doi=10.1002%2fehf2.12551&partnerID=40&md5=ef24df3848cf1a25e3dbdee0e4322d87https://remedy.med.bg.ac.rs/handle/123456789/5306While anti-cancer therapies, including chemotherapy, immunotherapy, radiotherapy, and targeted therapy, are constantly advancing, cardiovascular toxicity has become a major challenge for cardiologists and oncologists. This has led to an increasing demand of cardio-oncology units in Europe and a growing interest of clinicians and researchers. The Heart Failure 2019 meeting of the Heart Failure Association of the European Society of Cardiology in Athens has therefore created a scientific programme that included four dedicated sessions on the topic along with several additional lectures. The major points that were discussed at the congress included the implementation and delivery of a cardio-oncology service, the collaboration among cardio-oncology experts, and the risk stratification, prevention, and early recognition of cardiotoxicity. Furthermore, sessions addressed the numerous different anti-cancer therapies associated with cardiotoxic effects and provided guidance on how to treat cancer patients who develop cardiovascular disease before, during, and after treatment. © 2019 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of CardiologyCancerCardiotoxicityHeart failure